Skip to main
IDXX

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories (IDXX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

IDEXX Laboratories has achieved a remarkable customer retention rate of approximately 97%, which enhances the predictability of its revenue and earnings streams. The company has demonstrated strong growth potential with a 16% compound annual growth rate (CAGR) in organic consumables recurring revenue from 2016 to 2022, indicating robust demand for its diagnostic products and services. Additionally, customers utilizing IDEXX's full suite of offerings experience 3.5 times higher growth across various categories of testing, further supporting the company's favorable growth trajectory in the pet healthcare market.

Bears say

IDEXX Laboratories has experienced a concerning trend in clinical vet visits, which declined by 1.7% year-over-year in the fourth quarter of 2025, indicating a potential ongoing weakening in demand for its diagnostic products and services. This decline in pet patient visits, coupled with an expected further decrease of 200 basis points in pet visits in 2026, primarily attributed to economic pressures on lower-income pet owners, raises significant concerns about slower adoption of IDEXX's product portfolio. Additionally, economic downturns could impact both customers and suppliers, potentially leading to decreased demand for IDEXX's offerings and hampering revenue growth amidst these challenging market conditions.

IDEXX Laboratories (IDXX) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IDEXX Laboratories (IDXX) Forecast

Analysts have given IDEXX Laboratories (IDXX) a Buy based on their latest research and market trends.

According to 9 analysts, IDEXX Laboratories (IDXX) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $712.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $712.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IDEXX Laboratories (IDXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.